Acarix applies for entry on Nasdaq First North Premier in Stockholm.

The capital contribution which the company pertain to obtain in connection to the entry is worth 140 million SEK, already secured through description and garantee undertakings. The capital from the entry will mainly go to the company’s commercialization strategy and their planned launch of its already CE marked CADScor System during Q2 2017, with initial focus on Germany, UK, Sweden and Denmark.

Last week, the Chinese company Puhua Jingxin Guzhou Health Management Partnership made an extensive investment in the company and Puhua Jingxin will also issue shares in the upcoming entry.

“Coronary Artery Disease affects more than 120 million people worldwide but the current diagnostic pathway, which can rapidly escalate to expensive imaging and invasive coronary angiography, is inefficient”. He continues: “a recent Danish study showed that more than 90% of patients presenting CAD like symptoms to their general practitioner do not have CAD”. With the Acarix CADScor®System Acarix can provide an easy to use non-invasive tool able to rule out CAD with 96% negative predictive value. Christiansen concludes: “this translates into a potential to reduce onward patient referrals by ~50%. – a win-win for patients, payers and physicians,” says Søren Rysholt Christiansen, CEO of Acarix.